European Commission pilot project on repurposing brings value added innovation to life

28 October 2021

Innovation on existing, well-known molecules through repurposing can deliver huge benefits for patients and address unmet medical needs sustainably. Today […]

Digitalisation the key to efficient EU pharmaceutical regulation and easing of localised drug shortages

27 October 2021

“Digitalisation the key to efficient EU pharmaceutical regulation and easing […]

“Central Role For Industry Beckons As Europe Rebuilds After COVID” – Interview to Rebecca Guntern

25 October 2021

Generics And Biosimilars Must Become A Central Policy Pillar, Says […]

Smart use of off-patent medicines will be critical to rebuild healthcare systems successfully post-Covid

7 October 2021

Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe

1 October 2021

Rebecca Guntern (Sandoz) today begins an interim term as President […]

HERA must address outstanding weaknesses in EU pharma framework to be successful

16 September 2021

Medicines For Europe strongly supports the EU’s drive to learn from COVID-19 […]

Arun Narayan, Chairman of the Value Added Medicines Sector Group interviewed by the European Pharmaceutical review

8 September 2021

EU must take the lead to ensure security of supply for medicines

16 June 2021

Legislative reforms aligned with current off-patent market conditions are the […]

EU Industry Welcomes New Schengen Strategy’s Green Lanes

4 June 2021

“EU Industry Welcomes New Schengen Strategy’s Green Lanes” Read more

Opinion piece by Christoph Stoller for Friends of Europe

3 June 2021

“Too much at stake in the EU pharma strategy to […]